2020 Revenues ($USD) : $45,572,000,000
2020 R&D spend : $9,563,000,000
2020 Number of Employees : 43,000
Fiscal Year End : 1/3/2021
Key People : Alex Gorsky, chair and CEO, Johnson & Johnson; Jennifer Taubert, EVP and worldwide chair, Pharmaceuticals

While Johnson & Johnson tops some lists of the largest pharmaceutical companies, the conglomerate ranks sixth in our list based on its drug sales alone. Its Janssen segment has a broad therapeutic focus, including immunology, infectious disease, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Titusville, N.J.–based business that became part of Johnson & Johnson in 1961 drove $45.6 billion in revenue in 2020. One of the company's best-selling drugs is the immunosuppressive drug Stelara (ustekinumab), which raked in $7.7 billion in revenue in 2020. Other notable products include Remicade for immune-mediated inflammatory diseases, the rheumatoid arthritis treatment Simponi, Darzalex for multiple myeloma and the plaque psoriasis drug Tremfya. Janssen had announced first-quarter vaccine sales of $110 million and projected that it would manufacture one billion doses by the end of 2021. Demand for the COVID-19 vaccines in general, however, appears to be slipping in the U.S. –BB